IL-32 is a molecular marker of a host defense network in human tuberculosis.
about
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisMycobacterium bovis Infection of Cattle and White-Tailed Deer: Translational Research of Relevance to Human TuberculosisTricks to translating TB transcriptomics.Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis.S100A12 Is Part of the Antimicrobial Network against Mycobacterium leprae in Human Macrophages.Understanding immune protection against tuberculosis using RNA expression profilingCytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species.Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies.Association of Plasma IL-32 Levels and Gene Polymorphisms with Systemic Lupus Erythematosus in Chinese Han Population.Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosyEpipolymorphisms associated with the clinical outcome of autoimmune arthritis affect CD4+ T cell activation pathways.Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette-Guérin.Role of vitamin D in cytotoxic T lymphocyte immunity to pathogens and cancer.Simultaneous analysis of multiple T helper subsets in leprosy reveals distinct patterns of Th1, Th2, Th17 and Tregs markers expression in clinical forms and reactional events.Bolstering Immunity through Pattern Recognition Receptors: A Unique Approach to Control Tuberculosis.Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients.Imatinib Triggers Phagolysosome Acidification and Antimicrobial Activity against Mycobacterium bovis Bacille Calmette-Guérin in Glucocorticoid-Treated Human Macrophages.Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32.Role of interleukin-32 in the mechanism of chronic inflammation in IgG4-related disease and as a predictive biomarker for drug-free remission.Dendritic Cell-Derived IL-32α: A Novel Inhibitory Cytokine of NK Cell Function.SaVanT: a web-based tool for the sample-level visualization of molecular signatures in gene expression profiles.Anti-inflammatory therapies of amyotrophic lateral sclerosis guided by immune pathwaysInterleukin-32 is highly expressed in lesions of hidradenitis suppurativa.Th1 cytokines, true functional signatures for protective immunity against TB?Prospective study of immunomodulation in osteoarticular tuberculosis non responsive to anti tubercular therapy.Transcriptomic Analysis of CD4+ T Cells Reveals Novel Immune Signatures of Latent Tuberculosis.Vitamin D status contributes to the antimicrobial activity of macrophages against Mycobacterium lepraeGenetic Resistance to Infection and DiseaseThe Biology and Role of Interleukin-32 in Tuberculosis
P2860
Q26746099-84F83870-E3B7-4AC2-A762-8A9416547ED0Q28083909-02E05B33-6115-4D6C-95EB-8A18026C2CEEQ30488016-7A43D252-9DAA-4936-9165-5111A1274EE1Q35549372-8082340B-0A7E-49BA-B6EF-6FE00D5BC6F8Q36063917-DCF34310-A85B-44E7-9EC2-7A87BB263162Q36092310-FB2ED05B-6375-4AF9-92FB-B8CCC807B957Q36291428-1F4AC5EC-DD09-4502-B475-E959884726ACQ36654001-B9CBA933-AAFA-4813-850F-879A2C68FAE0Q36680867-5C7F28F9-64C5-477F-84DC-831C5F27D3D9Q37277036-6972B24A-9404-4068-803F-978CAB0D3927Q37473831-DA193E84-8F9A-4181-9D8F-7D33F8EFBF17Q37737540-F8D9EA56-11BB-4CE8-9AE4-043E01B0700FQ38610901-C9794CB6-66A1-4D94-B1C2-8BBA8A41B8EDQ40065350-6CC0AE76-EF45-4094-809F-E7EDDC5F43B9Q40086314-41092001-CA8B-45A1-B11D-3C510626F901Q40216038-9AB8B98A-3FD7-4BC4-A834-134E6EDFFC6DQ40656316-CE74AD51-1733-4FC8-BFD7-EDE91A288F24Q40858793-83770D34-C8A5-4A39-849A-84D7FD0B0486Q40997230-5DCC28EE-1D22-44B1-B011-BA915C1FE008Q41262546-AD7887F5-4764-4571-A6FC-213FB2DCF1E1Q42627854-ECF9B0AF-068F-4766-9319-45A7E1BBF0F5Q42772755-3687D23A-D6FB-4788-8209-902013018327Q48114983-D04D3561-D72A-4137-A844-857883B8ACFDQ49900955-F638B5E9-D705-4415-B59F-640B363F8E7FQ52599836-C3A5179C-DFB5-42E3-8C9A-E4C47F3F8C56Q52618127-DDD596D9-42C6-44B8-8D5B-5D14224E2091Q57081044-D3672740-FD4A-4AA4-B70E-9F3D676BDDF3Q57490834-D3C00C22-CFB2-43F4-8F40-7C3DAD0D9593Q58694023-1F40368C-F197-4DCE-A4CD-C18A1501C7FE
P2860
IL-32 is a molecular marker of a host defense network in human tuberculosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
IL-32 is a molecular marker of a host defense network in human tuberculosis.
@en
type
label
IL-32 is a molecular marker of a host defense network in human tuberculosis.
@en
prefLabel
IL-32 is a molecular marker of a host defense network in human tuberculosis.
@en
P2093
P2860
P50
P1476
IL-32 is a molecular marker of a host defense network in human tuberculosis
@en
P2093
Barry R Bloom
Dennis Montoya
John S Adams
Kathryn Zavala
Marcos A Munoz
Martin Hewison
Megan S Inkeles
Phillip T Liu
Poorva Vaidya
Steve Horvath
P2860
P304
P356
10.1126/SCITRANSLMED.3009546
P407
P577
2014-08-01T00:00:00Z